Japanese pharmaceutical company Eisai has teamed up with US-based Merck in a deal intended to strengthen the worldwide development and commercialisation of cancer drug Lenvima.
More than £500 million worth of life sciences and healthcare agreements were signed between the UK and China during the UK Prime Minister’s visit to China earlier this month.
Allergan is set to acquire Australia-based Elastagen, a clinical-stage company focused on developing medical device products based on recombinant tropoelastin, for $95 million.
AstraZeneca has announced partnerships with Chinese companies Alibaba and Tencent, in agreements that will use emerging technologies to improve healthcare in China.
Japan-based Abe & Partners has promoted Michiko Kinoshita as partner and Tomohiro Kazama as counsel.
Southeast Asia-based law firm Tilleke & Gibbins has appointed an IP enforcement specialist to partner.
Singapore-based Aslan Pharmaceuticals has acquired the full global rights to develop, manufacture and commercialise a cancer treatment.
Basilea Pharmaceutica and Pfizer have reached a deal for a licence agreement for the antifungal medication Cresemba to cover China and 16 countries in the Asia-Pacific region.
CPA Global has found that Sanofi files the most patents covering human gene therapy and also spends the most on them overall.
A patent counsel at Eli Lilly discussed a recent dispute pitting Amgen against Sanofi and Regeneron, saying an appeals court ruling was convoluted.